Q4 2024 · 13F-HR
CAXTON CORPholdings as filed
Filed 2025-02-14 · accession 0000919574-25-001439
$16.6M
Reported value
15
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 98422E103 | XERS | XERIS BIOPHARMA HOLDINGS INC | $6.8M | 41.1% | 2,015,157 | Common | SOLE |
| 76200L309 | RZLT | REZOLUTE INC | $6.5M | 38.8% | 1,318,967 | Common | SOLE |
| 78462F103 | SPY | SPDR S&P 500 ETF TR | $1.7M | 9.94% | 2,823 | Common | SOLE |
| 084670702 | BRK/B | BERKSHIRE HATHAWAY INC DEL | $513,554 | 3.09% | 1,133 | Common | SOLE |
| 78463V107 | GLD | SPDR GOLD TR | $283,068 | 1.70% | 1,169 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $237,149 | 1.43% | 34,073 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $190,593 | 1.15% | 10,941 | Common | SOLE |
| 52886X107 | LXEO | LEXEO THERAPEUTICS INC | $117,460 | 0.71% | 17,851 | Common | SOLE |
| 501976104 | KYTX | KYVERNA THERAPEUTICS INC | $85,950 | 0.52% | 22,981 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $63,025 | 0.38% | 43,465 | Common | SOLE |
| 14147L108 | CRDF | CARDIFF ONCOLOGY INC | $57,665 | 0.35% | 13,287 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $53,277 | 0.32% | 16,393 | Common | SOLE |
| 38000Q102 | GLYCEUR | GLYCOMIMETICS INC | $50,895 | 0.31% | 203,578 | Common | SOLE |
| 21077P108 | CNTX | CONTEXT THERAPEUTICS INC | $19,324 | 0.12% | 18,403 | Common | SOLE |
| 007002108 | TORCEUR | ADICET BIO INC | $16,823 | 0.10% | 17,488 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.